MiNK Therapeutics Inc News - INKT | Aktien NASDAQ

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical...

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:November 08, 2022...

Current Report Filing (8-k)

0001840229 False 0001840229 2022-11-03 2022-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATESSECURITIES AND EXCHANGE...

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

- Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy...

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical...

MiNK Therapeutics to Host R&D Event November 10, 2022

Experts in disease pathways discuss clinical data of allo-iNKTsR&D strategy driving pipeline momentum...

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumorsClinical data of...

6
7
8
Weiter

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

MiNK Therapeutics Inc (INKT)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

INKT Nachrichten

Statement of Changes in Beneficial Ownership (4)

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

Notice of Effectiveness (effect)

Current Report Filing (8-k)

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

MiNK Therapeutics to Host R&D Event November 10, 2022

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

INKT Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

MiNK Therapeutics Inc (INKT) News

MiNK Therapeutics Inc (INKT)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

INKT Nachrichten

Statement of Changes in Beneficial Ownership (4)

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

Notice of Effectiveness (effect)

Current Report Filing (8-k)

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

MiNK Therapeutics to Host R&D Event November 10, 2022

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

INKT Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen